BASEL, SWITZERLAND--(Marketwire - October 28, 2011) - Processed and transmitted by Thomson
The issuer is solely responsible for the content of this announcement.
Basilea Pharmaceutica Ltd. (SWISS: BSLN)
announced today that its board of directors has set November 29, 2011 as
for the extraordinary general meeting of shareholders.
The board of directors of Basilea has set November 29, 2011 as the date for
extraordinary general meeting of shareholders that was requested by
HBM BioVentures (Cayman) Ltd. The single agenda item is the election of
additional board members to expand the current board.
Following discussions between Basilea and HBM BioVentures, HBM BioVentures
proposes Dr. Thomas M. Rinderknecht, Mr. Domenico Scala and Dr. Thomas
additional members to the board. The board of directors of Basilea supports
election of the proposed candidates.
The invitation to the extraordinary general meeting of shareholders will be
published in the Swiss Official Gazette of Commerce at least 20 days prior
the extraordinary general meeting of shareholders. The board has set
17, 2011 as the deadline for registration in the share register in order to
participate and vote at the extraordinary general meeting of shareholders.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
the SIX Swiss Exchange (SIX: BSLN). Basilea Pharmaceutica International
fully integrated research and development operations are focused on
antifungals and oncology drugs, as well as on the development of
drugs, targeting the medical challenge of resistance and non-response to
treatment options in the hospital and specialty care setting.
Basilea is currently marketing Toctino® (alitretinoin), the only
treatment for adults with severe chronic hand eczema unresponsive to potent
topical corticosteroids, in Denmark, Finland, France, Germany, Norway,
Switzerland and the United Kingdom and has appointed distributors for
in other selected European markets, Canada, Israel, Mexico and the Republic
Korea. A phase III clinical program on alitretinoin for the treatment of
chronic hand eczema is ongoing in the U.S.
For its phase III compound isavuconazole, a potential best-in-class azole
antifungal for the treatment of life-threatening invasive fungal
company has entered into a license, co-development and co-promotion
with Astellas Pharma Inc.
In addition, Basilea is developing ceftobiprole, a late-stage novel anti-
(methicillin-resistant Staphylococcus aureus) broad-spectrum cephalosporin
antibiotic, for the first-line treatment of potentially life-threatening
resistant bacterial infections. Ceftobiprole has a broad coverage of both
positive bacteria, including MRSA, and many clinically important Gram-
bacteria such as Pseudomonas spp.
Basilea's BAL30072, a novel antibiotic for the treatment of resistant Gram-
negative infections, and the oncology drug BAL101553 for the treatment of
resistant cancers are in phase I clinical testing.
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
or achievements of Basilea Pharmaceutica Ltd. to be materially different
any future results, performance or achievements expressed or implied by
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
--- End of Message ---
Basilea Pharmaceutica AG
P.O Box Basel Switzerland
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE